Mathematica-mpr.com is now Mathematica.org. Please update your bookmarks. Learn more about this change.
Making Decisions About Stopping Medicines for Well‐Controlled Juvenile Idiopathic Arthritis: A Mixed‐Methods Study of Patients and Caregivers
Objective. Improved treatments for juvenile idiopathic arthritis (JIA) have increased remission rates. We investigated how patients and caregivers make decisions about stopping medications for well‐controlled JIA.
Methods. We performed a mixed‐methods study of caregivers and patients affected by JIA, recruited through social media and flyers and selected by purposive sampling. Participants discussed their experiences with JIA, medications, and decision‐making through recorded telephone interviews. Of 44 interviewees, 20 were patients (50% <18 years) and 24 were caregivers (50% of children ≤10 years). We evaluated characteristics associated with high levels of reported concerns about JIA or medicines using Fisher's exact testing.
Results. Decisions about stopping medicines were informed by competing risks between disease and treatment. Participants who expressed more concerns about JIA were more likely to report disease‐related complications (P=0.002) and more motivated to continue treatment. However, participants expressing more concern about medicines were more likely to report treatment‐related complications (P=0.04) and felt more compelled to stop treatment. Additionally, participants considered how JIA or treatments facilitated or interfered with their sense of normalcy and safety, expressed feelings of guilt and regret about previous or potential adverse events, and reflected on uncertainty and unpredictability of future harms. Decision‐making was also informed by trust in rheumatologists and other information sources, e.g., family, online support groups.
Conclusion. When deciding whether to stop medicines for well‐controlled JIA, patients and caregivers weigh competing risks between disease and treatment. Based on our results, we suggest specific approaches for clinicians to perform shared decision‐making around stopping medicines for JIA.